Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as G2-TR intraocular implant containing travoprost
G2-TR intraocular containing travoprost · 2 trials · 2 indications
Change from time-matched baseline in IOP at 8AM and 10AM at Day 10, Week 6 and Month 3. Day 10 8AM IOP minus Baseline 8AM IOP; Day 10 10AM IOP minus Baseline 10AM IOP; Week 6 8AM IOP minus Baseline 8AM IOP; Week 6 10AM IOP minus Baseline 10AM IOP; Month 3 8AM IOP minus Baseline 8AM IOP; Month 3 10AM IOP minus Baseline 10AM IOP.
| Arm | Type | Description |
|---|---|---|
| Implant Group 1 | EXPERIMENTAL | G2-TR intraocular implant containing Travoprost 75 mcg with high elution rate, plus postoperative placebo eye drops. |
| Implant Group 2 | EXPERIMENTAL | G2-TR intraocular implant containing Travoprost 75 mcg with low elution rate, plus postoperative placebo eye drops. |
| Control Group | ACTIVE_COMPARATOR | Sham surgery + active-comparator eye drops |
| Name | Type | Description |
|---|---|---|
| G2-TR intraocular implant containing travoprost | COMBINATION_PRODUCT | Provided in Arm/Group descriptions |
| Sham surgery + active-comparator eye drops | DRUG | Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%) |
Inclusion Criteria: * Diagnosed with open-angle glaucoma or ocular hypertension * C/D ratio ≤ 0.8 * Zero to two preoperative ocular hypotensive medications Exclusion Criteria: * Active corneal inflammation or edema * Retinal disorders not associated with glaucoma
G2-TR intraocular containing travoprost is an investigational small molecule therapy developed by Glaukos Corporation for open-angle glaucoma. It is designed as an intraocular implant that delivers travoprost directly inside the eye. The product is in Phase 3 clinical development and has been studied in two completed trials.
G2-TR intraocular containing travoprost is being developed for the treatment of open-angle glaucoma. The clinical trials also enrolled patients with ocular hypertension. It is intended to provide sustained delivery of travoprost to lower intraocular pressure in these conditions.
G2-TR intraocular containing travoprost is developed by Glaukos Corporation, which trades on the New York Stock Exchange under the ticker symbol GKOS. Glaukos is an ophthalmology-focused pharmaceutical and medical device company.
G2-TR intraocular containing travoprost is in Phase 3 clinical development. Two Phase 3 trials have been completed, and no active trials are currently listed. It is an investigational product and has not been approved by the FDA.
G2-TR intraocular containing travoprost has been evaluated in two completed Phase 3 trials. NCT03868124 compared two models of the travoprost intraocular implant in 560 patients. NCT03519386 compared two implant models to timolol maleate ophthalmic solution 0.5% in 590 patients. Both enrolled adults with open-angle glaucoma or ocular hypertension.
Yes, G2-TR intraocular containing travoprost is also known as G2-TR intraocular implant containing travoprost. The two names refer to the same investigational product from Glaukos Corporation.